Is LRN or UTI a better buy right now?

Based on our latest analysis, LRN is currently the stronger investment candidate based on our comprehensive scoring model.

Does LRN or UTI have better growth?

Our analysis compares revenue and earnings growth. Check the 'Growth' section above to see which company is expanding faster. Typically, the stock with higher revenue growth rates is considered the better growth stock.

Which stock is cheaper: LRN or UTI?

We compare P/E ratios and other valuation metrics in the 'Valuation' section. The stock with the lower P/E ratio is generally considered 'cheaper' relative to its earnings, though growth prospects must also be considered.

Which is the better buy right now, LRN or UTI?

As of Oct 02, 2026, LRN scores higher in our model: LRN has an AI score of 59.7 versus 46.2 for UTI. LRN is currently in a Markdown technical phase and UTI is in a Markdown phase. Consider both scores and phases alongside your own risk tolerance.

What technical phase are LRN and UTI in?

LRN is in a Markdown phase (Sell / avoid) with an RSI of 40.0. UTI is in a Markdown phase (Sell / avoid) with an RSI of 31.7.

LRN vs UTI

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 02, 2026

LRN

59.7

AI Score

LRN Wins

UTI

46.2

AI Score

Investment Advisor Scores

LRN

60score

Recommendation

HOLD

View Full Analysis

UTI

46score

Recommendation

HOLD

View Full Analysis

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric	LRN	UTI	Winner
Revenue	1.88B	661.15M	LRN
Net Income	256.80M	15.54M	LRN
Net Margin	13.6%	2.4%	LRN
Operating Income	344.92M	19.27M	LRN
ROE	15.6%	4.5%	LRN
ROA	10.5%	1.7%	LRN
Total Assets	2.45B	897.86M	LRN
Cash	614.05M	130.06M	LRN
Debt/Equity	0.25	0.46	LRN
Current Ratio	6.21	1.30	LRN
Free Cash Flow	116.38M	-63.50M	LRN

Relative Price Performance (Last 90 Days)

LRN 1M: -11.2% · 3M: -14.3% UTI 1M: -8.7% · 3M: -60.6%

Current Technical Phase

LRN

Markdown

Sell / avoid

Price below a falling SMA50 (slope -3.4%), weak momentum, RSI 40

RSI (14): 40.0 · Price: $77.52

UTI

Markdown

Sell / avoid

Price below a falling SMA50 (slope -26.6%), weak momentum, RSI 32

RSI (14): 31.7 · Price: $19.03

Fundamentals Snapshot

Metric	LRN	UTI
Market Cap	—	—
Forward P/E	8.9	25.9
Trailing P/E	10.6	30.6
Revenue (TTM)	—	—
Revenue Growth	0.0%	0.1%
Gross Margin	0.4%	0.6%
Operating Margin	0.2%	0.0%
EPS	7.37	0.61
Dividend Yield	—	—

Frequently Asked Questions

Based on our detailed analysis, LRN is currently the stronger investment candidate, winning 11 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.

Related Analysis

LRN

UTI

Data derived from SEC EDGAR filings and Tradestie proprietary analysis. Last updated: Oct 02, 2026 05:38 UTC. Refresh Data

Tradestie